

1 **Chitosan/collagen biomembrane loaded with 2,3-dihydrobenzofuran for the**
2 **treatment of cutaneous Leishmaniasis**

3 *Elton Marks Araujo Braz^a, Solranny Carla Cavalcante Costa Silva^{a,b}, Michel Muálem*
4 *Moraes Alves^{c,d}, Fernando Aécio Amorim Carvalho^{c,*}, Rui Magalhães^e, Josy Antevelli*
5 *Osajima^a, Durcilene Alves Silva^{a,*}, Ana Leite Oliveira^{e,*}, Edvani Curti Muniz^{a,f}, Edson*
6 *Cavalcanti Silva-Filho^{a,*,#}*

7
8 ^a Laboratório Interdisciplinar de Materiais Avançados – LIMAV, Universidade Federal
9 do Piauí, Campus Ministro Petrônio Portella, Teresina, PI - 64049-550, Brazil.

10 ^b Universidade Estadual do Piauí, Campus Professor Ariston Dias Lima, São Raimundo
11 Nonato, PI - 64770-000, Brazil.

12 ^c Núcleo de Pesquisa em Plantas Mediciniais – NPPM, Universidade Federal do Piauí,
13 Campus Ministro Petrônio Portella, Teresina, PI - 64049-550, Brazil.

14 ^d Departamento de Morfofisiologia Veterinária, Universidade Federal do Piauí, Campus
15 Ministro Petrônio Portella, Teresina, PI - 64049-550, Brazil.

16 ^e Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina –
17 Laboratório Associado, Escola Superior de Biotecnologia- Porto - 4169-005, Portugal.

18 ^f Universidade Estadual de Maringá, Departamento de Química, Maringá, PR – 87020-
19 970, Brazil.

20
21 *Joint senior authors


22 # Correspondent author. E-mail: edsonfilho@ufpi.edu.br

23
24
25
26
27

28 **GRAPHIC ABSTRACT**

29

30



31



32

33

34

35 **HIGHLIGHTS**

- 36 • Biomembrane has potential for the treatment of cutaneous Leishmaniasis.
- 37 • The biomembrane stimulated the proliferation of human keratinocyte – HaCaT.
- 38 • AFM images showed excellent results in inhibiting parasite growth.

39

40

41

42

43 **ABSTRACT**

44 In this work, a chitosan/collagen-based membrane loaded with 2,3-dihydrobenzofuran
45 (2,3-DHB) was developed through a simple solvent-casting procedure for use in the
46 treatment of cutaneous **Leishmaniasis**. The obtained membranes were characterized by
47 elemental analysis, FTIR, TG, DSC, and XRD. Porosity, swelling, mechanical properties,
48 hydrophilicity, and antioxidant activity were analyzed. In addition, an assessment of the
49 biocompatibility with fibroblasts and keratinocytes and of the *in vitro* wound healing was
50 performed. The obtained results show that the new 2,3-DHB loaded chitosan/collagen
51 membrane presented high porosity and swelling capacity as well as maximum strength,
52 hydrophilicity, and antioxidant activity higher in relation to the control. The tests of
53 antileishmanial activity and the AFM images great efficacy of inhibition growth of the
54 parasite, superior to those of Amphotericin B, the standard therapeutic agent that is
55 currently used. The new membranes are biocompatible and stimulated the proliferation
56 of keratinocytes. SEM images clearly demonstrate that fibroblasts were able to adhere
57 maintained their characteristic morphology. The healing test evidenced that the
58 membranes have an adequate environment for promoting cell proliferation and growth.
59 The new membrane proved to be an excellent candidate to treat cutaneous **Leishmaniasis**
60 and is clearly indicated for further advanced studies *in vivo*.

61 Keywords: Polysaccharide; *Leishmania amazonensis*; wound treatment.

62

63

64

65

66

1. INTRODUCTION

67 Leishmaniasis are diseases caused by protozoa **that belongs** to the *Leishmania*
68 genus. They are part of the neglected infectious diseases group with a wide global
69 distribution since they affect the most vulnerable populations in the poorest countries [1].
70 The current pharmacological treatment of **Leishmaniasis** consists of limited therapies,
71 which cause serious side effects, and the majority of the drugs used are only effective
72 when administered parenterally, requiring long periods of therapy [2,3]. In addition, the
73 parasites that cause **Leishmaniasis** have become resistant to drugs conventionally used in
74 medical treatments [4,5], which makes the research of new antileishmanial compounds
75 or alternative treatment therapies essential.

76 *L. amazonensis* causes cutaneous **Leishmaniasis** in humans and domestic animals
77 [6,7], with a variety of symptoms, from self-healing infections to disfiguring chronic
78 illnesses [8]. 2,3-dihydrobenzofuran (2,3-DHB) is a neolignan that recently has been
79 studied for its potential as an antileishmania agent. It promoted high *in vitro*
80 antileishmanial activity in the promastigote and amastigote forms of *Leishmania*
81 *amazonensis*, with minimal cytotoxic effects in murine macrophages and human red
82 blood cells. In addition, 2,3-DHB stimulated increased lysosomal volume, phagocytic
83 capacity, and production of nitric oxide in macrophages, which are mechanisms possibly
84 involved in its antileishmanial effect [9]. In this sense, 2,3-DHB could be used *in situ*,
85 against the parasite that causes cutaneous **Leishmaniasis**, which produces wounds that are
86 difficult to heal. Also, if incorporated as an active principle into a wound dressing, it could
87 be useful to add leishmanicidal activity, while promoting wound healing.

88 Some biopolymers, such as collagen and chitosan, have already been widely used
89 to treat wounds due to their intrinsic properties. Collagen is a fibrous protein that
90 contributes to physiological functions of tissues in skin, tendons, bones, and cartilage

91 [10]. Furthermore, collagen has characteristics of biocompatibility, degradation, low
92 antigenicity and plays an important role in tissue healing [11–13] since it provides the
93 biological microenvironment for cell growth, supporting cell binding, migration, and
94 proliferation [14,15]. Many collagen-related products have been developed in the recent
95 years for wound healing, which demonstrates well its value as a biopolymer in
96 regenerative medicine [16,17]. Chitosan is another well-known material for several
97 applications [18,19], and its biocompatibility, biodegradability, non-toxicity,
98 mucoadhesion, antimicrobial activity have been widely studied. This low cost and
99 abundant polysaccharide [20–23] can promote wound healing, improving the functions
100 of fibroblasts, macrophages and inflammatory cells [24], while exhibiting excellent
101 film/membrane forming properties and water absorption capacity [25–27].

102 In addition, the combination of chitosan and collagen properties leads to
103 improved materials that can be used to improve the healing of skin wounds [15,28],
104 without causing inflammatory reaction [29], while simultaneously acting as a vehicle to
105 release drugs such as dexamethasone [30] and gentamicin [31] due to their inherent
106 properties. Consequently, anti-inflammatory drugs, pro-proliferative drugs and pre-
107 synthesized membranes can be combined and employed to accelerate wound healing.
108 Thus, a chitosan/collagen membrane with associated 2,3-DHB could be an excellent
109 option for the treatment of cutaneous *Leishmaniasis*. Therefore, the objective of this work
110 was to develop, for the first time, a membrane based on chitosan, collagen, and 2,3-DHB
111 to treat wounds caused by *Leishmania*.

112

113 **2. EXPERIMENTAL PART**

114 **2.1 Materials and reagents**

115 Chitosan with medium degree of deacetylation 78% was obtained from Polymar.
116 Hydrolyzed collagen of bovine origin was obtained from Relva Verde Alimentos Ltda.
117 (Paraná, Brazil). To test antileishmanial activity, the promastigote forms of *L.*
118 *amazonensis* (IFLA/BR/67/PH8) were provided by the Antileishmanial Activity
119 Laboratory at the Federal University of Piauí. The antibiotic
120 (penicillin/streptomycin/amphotericin B) and trypsin were supplied by Lonza, USA. The
121 reagents 2,3-dihydrobenzofuran (2,3-DHB), acetic acid, absolute ethanol, potassium
122 persulfate, methanol, glutaraldehyde, dimethylsulfoxide (DMSO), MTT (3- [4,5-
123 dimethylthiazol-yl]-2,5-diphenyltetrazolium bromide), phosphate-saline buffer (PBS),
124 Schneider's medium, resazurin, ABTS [2,2-azino-bis (3-ethylbenzothiazoline-6-
125 sulphonic acid)] and trolox were from Sigma-Aldrich. The human keratinocyte cell line
126 (HaCaT) was obtained from Cell Line Services (Oppenheim, Denmark) and were
127 cultured, as well as, the mouse fibroblast cells, L929 (NCTC) (ECACC 85103115), at
128 37 °C in a humidified atmosphere of 95% air and 5% CO₂, as monolayers using
129 Dulbecco's Modified Eagle's Medium (DMEM) with 4.5 g.L⁻¹ glucose, L-glutamine
130 without pyruvate (Lonza, Verviers, Belgium) containing 10% (v/v) fetal bovine serum
131 (FBS, Biowest, Nuaille, France) and 1% (v/v) Penicillin-Streptomycin-Fungizone
132 (Lonza, Verviers, Belgium). The water used for the synthesis processes was obtained by
133 purification in a Milli-Q system (Millipore Corporation). All reagents were used without
134 prior purification.

135 2.2 Membranes' production

136 A 2.0% w/v chitosan solution was prepared in 0.1 mol.L⁻¹ of acetic acid. After
137 stirring overnight, the solution was rested to remove bubbles. A 2.0% w/v collagen
138 solution was prepared in the same way. The two solutions were mixed in a 1:1 ratio and
139 this mixture was stirred for 3 h using a magnetic stirrer. The membranes were prepared

140 by solvent casting technique in 96-well plates (100.0 μL of the solution per well) and 24-
141 well plates (1000.0 μL of the solution per well) and dried in an oven for 48 h at 40 °C and
142 called MQC.

143 A different batch of samples was produced by adding 2,3-dihydrobenzofuran (2,3-
144 DHB) to the initial chitosan/collagen solution, to obtain a final concentration of 13.0
145 $\mu\text{mol.L}^{-1}$. This solution was stirred for 3 h and the membranes were prepared by solvent
146 casting according to the previously described procedure. These were designated MDHB.

147

148 2.3 Characterization

149 Thermogravimetric analysis (TG, DTG, and DSC) was performed on the TA
150 Instruments SDT Q600 V20.9 Build 20 device using approximately 10.0 mg of sample
151 with a heating rate of 10 °C min^{-1} in an Argon atmosphere with a flow of 100.0
152 mL.min^{-1} in an alumina sample holder in the temperature range from 25 to 800 °C. FTIR
153 spectra of the materials were obtained using the Varian 660-IR spectrophotometer in 32
154 scans in the region of 500 to 4000 cm^{-1} with a resolution of 4 cm^{-1} . Elementary analysis
155 of carbon, hydrogen, and nitrogen were carried out in a Perkin-Elmer device, model PE
156 2400. X-Ray Diffraction (XRD) was performed on a Shimadzu diffractometer, model
157 XR-D600 A, in the 2θ range between 5 and 75 °. The scanning speed was 5 ° min^{-1} , using
158 the $\text{CuK}\alpha$ radiation source, with a wavelength of 154.06 pm.

159 The hydrophilicity of the samples was determined by contact angle measurements
160 with the water using the sessile drop method on the Theta instrument (Biolin Scientific)
161 at 25.0 °C. In each membrane, a $4.0 \pm 0.2 \mu\text{L}$ drop of water was deposited on the sample
162 surface, and the video recorder was used to observe the interaction between the drop of
163 water and the surfaces of the membranes for 1 minute. Analyzes were performed in
164 quadruplicate.

165

166 **2.4 Degree of porosity and thickness of the membranes**

167 The degree of porosity of the membranes was measured by determining the
168 amount of ethanol absorbed after 1 h of immersion in this solvent, using
169 Equation (1) [32]:

170

$$171 \quad P(\%) = \frac{W_2 - W_1}{d_{ethanol} \cdot V_{membrane}} \times 100 \quad \text{Eq. (1)}$$

172

173 where, W_1 represents the weight of the dry membrane and W_2 is the weight of the wet
174 membrane, $d_{ethanol}$ the density of ethanol 100% (v/v) at room temperature, and $V_{membrane}$
175 is the volume of the membrane. To calculate the volume of the membrane, the radius was
176 measured with a digital caliper (Mitutoyo, Japan) and the thickness was measured with a
177 device for thickness measurement (Adamel Lhomargy, MI20, France).

178

179 **2.5 Swelling Degree**

180 The degree of swelling of the membranes was measured by the gravimetric
181 method [33]. The membranes, approximately 0.87 cm in diameter, were dried at 45 °C
182 for 1 h and weighed on an analytical balance. Then, they were immersed in PBS solution
183 at room temperature for 1 h. After this period, the membranes were removed from the
184 PBS solution and the excess was removed with filter paper before being weighed. The
185 degree of swelling of each sample was performed in quadruplicate and calculated from
186 the following Equation (2):

187

$$188 \quad \text{Swelling degree (\%)} = \frac{W_f - W_0}{W_0} \times 100 \quad \text{Eq. (2)}$$

189

190 where, W_0 is the initial dry weight of the membrane and W_f is the swollen weight of the
191 membrane after absorbing the PBS solution for 1 h.

192

193 **2.6 Mechanical tests**

194 Mechanical tests were performed on texturometer equipment (TA.XT plus
195 Texture Analyzer, Stable Micro Systems, Cardiff, UK). Force calibration for a 5 Kg load
196 cell was performed using a 2 Kg weight, and height calibration was performed using the
197 film support rig and corresponding probe. The thickness of each sample was measured
198 with a Micrometer MI 20 (Adamel Lhomargy, France). All analyzes were done at room
199 temperature, **ca. 25 °C**, and the maximum resistance to rupture of the membranes was
200 calculated in quintuplicate.

201

202 **2.7 Antileishmanial activity and Microscopy (AFM) analysis**

203 The assay was performed with promastigote forms of *L. amazonensis*
204 (IFLA/BR/67/PH 8) in logarithmic growth phase. The parasites were seeded in 96-well
205 cell culture plates containing supplemented Schneider medium, in the amount of 1×10^6
206 leishmania/100.0 μL of medium. Then, the membranes were added to the wells in
207 duplicate and serial dilutions were made, reaching six ranges of final concentrations (13
208 to $0.4 \mu\text{mol.L}^{-1}$). The plate was incubated in a Biochemical Oxygen Demand (BOD) oven
209 at a temperature of **26 °C** for 48 h, with 6 h remaining for the end of this period, $20.0 \mu\text{L}$
210 of resazurin $1 \times 10^{-3} \text{ mol.L}^{-1}$ were added. The absorbance reading was performed on a
211 plate reader (Biotek, model ELx800), at a wavelength of 550 nm, and the results were
212 expressed in terms of growth inhibition (%).

213 Microscopy (AFM) analysis of the treated and untreated *Leishmania amazonensis*
214 used samples fixed with glutaraldehyde (2%), after the previously mentioned experiment.

215 Then, the samples were washed 3× with PBS (0.1 mol.L⁻¹) by centrifugation (1100 × g
216 for 10 min at room temperature, ca.25 °C). The washed samples were placed (30.0 μL)
217 on a clean glass slide. After the drying time, the slides were washed twice with distilled
218 water and placed to dry again [34]. The study was carried out on TT-AFM equipment
219 (AFM, Workshop, USA) in vibrating mode (tapping mode) with silicon cantilever
220 (TAP300-G10, TED PELLA, INC) and resonance frequency of approximately 240 kHz.
221 Images of 29 × 29 μm with resolution of 512 × 512 pixels were obtained and the images
222 were processed using the Gwyddion 2.55 software.

223

224 **2.8 Antioxidant activity**

225 The ABTS [2,2-azino-bis(3-ethylbenzotiazoline-6-sulphonic acid)] assay was
226 carried out according to Policarpi *et al.* [35] with modifications. Briefly, the ABTS radical
227 (7.0 mmol.L⁻¹ – 0.0384 g ABTS, dissolved in 10.0 mL deionized water) was mixed with
228 potassium persulfate (2.44 mmol.L⁻¹ – 10.0 mL and 10.0 mL ABTS persulfate), the
229 solution was homogenized and stored in an amber flask in the dark for a minimum of 16
230 h. The ABTS solution was diluted with methanol to achieve an absorbance value of (0.700
231 ± 0.020) at 734 nm. Then 20.0 μL of extract stock solutions were added in 180.0 μL of
232 adjusted ABTS solution and after 5 min the absorbance at 734 nm was determined with
233 a microplate reader (Synergy H1, Vermont, USA). Trolox was used as the standard. The
234 analysis was performed in triplicate, and the results were expressed as a percentage of
235 reduction in absorbance compared to the control.

236

237 **2.9 Biocompatibility in fibroblasts and keratinocytes**

238 The cytotoxicity of MQC and MDHB was assessed through the cell viability of
239 murine fibroblasts - L929 and human keratinocytes - HaCaT using the MTT assay
240 following the standardized instructions according to ISO 10993-5.

241 HaCaT and L929 cell lines were seeded (1×10^4 cells/well) in 96-well microplates,
242 maintained in DMEM supplemented with 20% and 10% (v/v) fetal bovine serum (FBS),
243 respectively, and 1% (v/v) of antibiotics (penicillin/streptomycin/amphotericin B -
244 Lonza, USA). Simultaneously, the extracts of the MQC and MDHB samples were
245 prepared by adding 5.0 mg of each material to 1.0 mL of DMEM followed by incubation
246 at 37 °C for 24 h.

247 After the cells reached subconfluence inside the wells, the culture media were
248 carefully removed and replaced with MQC and MDHB extracts at concentrations of
249 39.06, 78.12, 156.25, 312.50, 625.00, 1250.00, 2500.00, and 5000.00 $\mu\text{g.mL}^{-1}$. After
250 incubation for 24 h, the extracts were replaced with 50.0 μL of 1.0 mg.mL^{-1} MTT
251 solution, prepared in DMEM without supplements, and incubated again for another 2 h.
252 Then, the MTT was replaced with 100.0 μL of DMSO and the microplate was stirred for
253 about 10 min, until the formazan was completely solubilized. After that, the optical
254 density at 570 nm was measured using a microplate reader (Multiskan Sky,
255 Thermoscientific).

256 As a positive control of cytotoxicity, DMEM medium was added with 20%
257 DMSO. As a negative control, of non-cytotoxic material, DMEM plus FBS and
258 antibiotics were used. The values of optical density (OD) obtained were converted into
259 percentages of relative cell viability of the sample and the negative control. All tests were
260 performed in triplicate and in three independent experiments.

261

262 **2.10 Morphological analysis of the fibroblasts**

263 For each well of a 24-well plate, a disc of TCPS (Tissue Culture Polystyrene) was
264 placed and, in sequence, L929 cells were sown in those wells (1×10^5 cells/well) in
265 DMEM medium supplemented with 10% fetal bovine serum and 1% of antibiotics, and
266 incubated at 37 °C and 5% of CO₂.

267 After this period, the culture medium was replaced by the extracts from the MQC
268 and MDHB membranes at a concentration of 5000.0 $\mu\text{g.mL}^{-1}$ and the plate was incubated
269 again, under the same conditions as the previous experiment, for 24 h. The extracts were
270 removed, the TCPS membranes were washed twice with PSB, and then the cells on the
271 TCPS membranes were fixed with at 2.5% (v/v) glutaraldehyde, by remaining in contact
272 with the glutaraldehyde solution for at least 1 h. Then, samples were washed by removing
273 the glutaraldehyde solution and substituting by deionized water, remaining in contact for
274 10 min. Afterwards samples were dehydrated by replacing deionized water with a
275 sequence of ethanol solutions with increasing concentration (30, 50, 70, 80, 90, and 100%
276 (v/v)). Each solution was left in contact with the samples for 10 min before being replaced
277 by the following concentration. After the final 10 min contact with absolute ethanol
278 (which was performed twice), the ethanol was removed and two drops (enough to cover
279 the entire sample) of hexamethyldisilazane (HMDS; Sigma-Aldrich, USA) were placed
280 over the samples and promptly evaporated to dryness with a nitrogen stream. Dried
281 samples were then placed in observation stubs (covered with double sided adhesive
282 carbon tape – NEM tape, from Nisshin, Japan) and coated with gold/palladium using a
283 Sputter Coater (Polaron, from Bad Schwalbach, Germany). Samples were analyzed in a
284 scanning electron microscope (SEM; JSM-5600LV, from JEOL, Japan) and observations
285 were performed in high-vacuum with an acceleration voltage of 15 kV.

286

287 **2.11 Wound Healing Assay**

288 To determine whether MQC and MDHB could alter the rate of cell migration in
289 HaCaT and, consequently, in wound healing, a scratch test was performed. This assay
290 was carried out as described by Pinto *et al.* [36] with some modifications. Briefly, 24-
291 well plates were seeded in DMEM medium supplemented with 10% Fetal Bovine Serum
292 (SFB) and 1% antibiotics (penicillin/streptomycin/amphotericin B), 500.0 μL of a cell
293 concentration of 2.0×10^5 cells.mL^{-1} , and the plates were incubated in BOD at 37°C and
294 5% CO_2 until cell confluence was reached in all wells. When the confluence was reached,
295 the culture medium was removed, then a vertical scratch was made in each well using a
296 200 μL tip, the cell monolayer was washed with 500.0 μL of PBS to remove cell
297 fragments. The sample extracts were added at a concentration of 1.0 mg.mL^{-1} , and the
298 cells were incubated again under the same conditions previously described. The extracts
299 were obtained as described in the biocompatibility assay section, at the concentration of
300 1.0 mg.mL^{-1} . The cells treated with supplemented culture medium were used as controls.
301 Wound closure was monitored through photographs taken at 0, 24, and 48 h using a
302 Moticam 1 camera (1280×720 pix) attached to the lens of an inverted microscope
303 (Axiovert 40 CFL Trinocular), observing the cells with the $10\times$ objective. The percentage
304 of wound closure, which reflects the rate of cell migration, was calculated based on the
305 spider widths determined using the ImageJ 1.52a software, according to Equation 3:

306

$$307 \quad \text{Percent closure (\%)} = \frac{(\text{initial scratch width}) - (\text{final scratch width})}{\text{initial scratch width}} \times 100 \quad \text{Eq. (3)}$$

308

309 The width averages were obtained with 10 measurements along the entire scratch.
310 The average of the initial width was that measured at $t = 0$ h, while the average of the
311 final width was that measured at 24 or 48 h. Three independent experiments were carried
312 out, each in quadruplicate.

313

314 2.12 Statistical analysis

315 For the biological tests, ANOVA analysis of variance was performed followed by
316 the Bonferroni test in Graph Pad Prism 5.0, taking the value of $p < 0.05$ as the maximum
317 level of statistical significance (95% confidence). For the other tests, the unpaired Student
318 t test was employed.

319

320 3. RESULTS AND DISCUSSION

321 3.1 Physicochemical characterization

322 Elementary analysis was used to investigate the chemical composition of each
323 sample. All the results of the elementary analysis of the membranes, expressed in
324 percentages and amounts in mmol.g^{-1} of carbon, nitrogen, and hydrogen, as well as the
325 carbon and nitrogen ratio, are listed in **Table 1**.

326

327 **Table 1** - Percentages of carbon (C), hydrogen (H), and nitrogen (N) and the molar quantities
328 of these elements for MQC and MDHB.

Sample	%			mmol.g^{-1}			C/N
	C	H	N	C	H	N	
MQC	38.55±0.14	8.56±0.29	6.34±0.07	32.13±0.12	85.60±2.90	4.53±0.05	7.09±0.10
MDHB	39.80±0.25	8.72±0.12	6.29±0.02	33.17±0.21	87.20±1.27	4.49±0.01	7.38±0.02

329

330 Initially, the MQC membrane presented 32.13 mmol.g^{-1} of carbon to
331 4.53 mmol.g^{-1} of nitrogen. With the insertion of the substance 2,3-DHB in the membrane
332 to form the MDHB membrane, as expected, the amount of nitrogen did not vary, but the
333 carbon changed to 33.17 mmol.g^{-1} causing the C/N ratio to increase from 7.09 to 7.38
334 mmol.g^{-1} . This increase occurred due to the presence of the new compound in the
335 membrane indicating its successful incorporation in the polymeric matrix.

336 Infrared spectroscopy, as well as other spectroscopic techniques, were used to
337 examine the formation of the membrane and the incorporation of 2,3-DHB. **Fig.1A**
338 presents the MQC and MDHB spectra.
339




Figure 1 - Infrared spectra of MQC and MDHB (A); 2,3-DHB TG and DTG curves (B); TG (C), DTG (D) curves of MQC and MDHB. (Melhorar a figura 1.d)


340
341 The FTIR spectrum of the MQC membrane showed a characteristic profile of
342 polysaccharide materials, consisting of chitosan and collagen, with bands around 3258
343 cm⁻¹ (Amide A), 1635 cm⁻¹ (Amide I), 1536 cm⁻¹ (Amide II), and 1069 cm⁻¹ (COC of the
344 polysaccharide structure) [30,37,38]. This indicates that the presence of collagen in the
345 chitosan membrane does not cause any significant change in chemical group oscillations
346 [39,40]. In the process of synthesizing this membrane, the collagen and chitosan were

347 dissolved in an acid medium, with ionization of the carbonyl groups of the collagen and
348 amine of the chitosan, producing an electrolytic reaction and interaction by electrostatic
349 attraction between them [30]. The binding occurred in the amino groups of chitosan and
350 collagen, belonging to amines I and II. Furthermore, carbonyl and collagen NH₂ groups
351 can form these same bonds with OH and NH₂ groups of chitosan [37].

352 The FTIR spectrum of the MDHB membrane displayed an increase in band
353 intensity around 3258 cm⁻¹, referring to the OH stretching of free water and the NH
354 stretching of amide A [18,41]. The appearance of new bands in the region between 2857
355 and 2893 cm⁻¹ and at 1397 cm⁻¹ refer to the aromatic ring present in the structure of 2,3-
356 DHB [42]. The bands related to the collagen triple helix are at 1635 cm⁻¹ (Amide I), 1536
357 cm⁻¹ (Amide II), and at 1250 cm⁻¹ (Amide III) [43,44], which is very important because
358 all the biological activity of collagen, including cell adhesion, depend on the structure of
359 the triple helix [45].

360 The interaction between 2,3-DHB and the matrix can be observed in the figure
361 below (Fig. 2). 2,3-DHB, which has an epoxide ring in its structure, is reactive due to ring
362 tension. In an acidic environment, the oxygen in the epoxide is protonated and can then
363 be attacked by the nucleophiles present in chitosan (-OH, -NH₂). The more substituted
364 carbon is more likely to be attacked, because a more substituted carbocation is more
365 stable. The product showed an increase in the number of hydroxyls (-OH) and C-O bonds.
366 Corroborating the increase in band intensities observed in the FTIR spectrum. The
367 presence of more hydroxyls in the structure also implies an increase in the hydrophilicity
368 of the material.

369



370

371

Figure 2 – Simplified scheme of the interaction of 2,3 DHB with chitosan.

372

373

Through thermogravimetric analysis (TG), an additional confirmation of the

insertion of the 2,3-DHB molecular structure in the new membrane was sought, in

addition to seeking to better understand their thermal stability. The TG and DTG curves

of the pure 2,3-DHB (**Fig. 1B**) evidenced that it degraded in a single step. In this mass

loss event, which occurred between 45 °C and 148 °C, with a maximum peak of DTG at

137 °C, all the material was degraded.

In thermogravimetric analyzes of the membranes (**Fig. 1C** and **Fig. 1D**) it was

possible to notice that the first mass loss event, which is related to the loss of structurally

bound water in the membranes, began at 50 °C for both MQC and MDHB. This event

had a maximum dehydration peak at approximately 97 °C for both membranes. Likewise,

it was possible to notice that the maximum decomposition peak of these membranes was

also similar (approximately 290 °C). These high decomposition temperatures are

important for future applications.

385

386 The thermogravimetric analysis of the membranes illustrated an additional
387 increase of a small event in MDHB between 126 – 204 °C, evidenced by a small shoulder
388 on the TG curve and a small peak in the DTG of this membrane for degradation of 2,3-
389 DHB grafted to MDHB. The temperature increases related to the degradation of 2,3-DHB
390 inserted in the membrane (170 °C), compared to pure 2,3-DHB (137 °C), suggests good
391 interaction between this substance and the polymeric matrix.

392 The results of DSC analysis of pure 2,3-DHB, MQC, and MDHB are provided in
393 **Fig. 3A.**

394




Figure 3 - DSC (A) and XRD (B) curves of MQC and MDHB.

395

396 The endothermic peak at around 100 °C for both MQC and MDHB was due to
397 dehydration of these materials [46,47]. An accentuated endothermic peak is visible for
398 2,3-DHB at 142.35 °C, due to the degradation of the substance, but this peak is not
399 observed in the MDHB membrane that carries the compound. This result suggests a
400 uniform and amorphous dispersion at the molecular level of 2,3-DHB into the membrane
401 matrix [48,49]. The MQC and MDHB membranes exhibited another endothermic peak
402 above 150 °C. Comparing this event in the two membranes elucidates an increase in the

403 enthalpy variation in the MDHB membrane (MQC = 63.31 J.g⁻¹ and MDHB = 81.95
404 J.g⁻¹). The increase in energy involved in this endothermic event is related to the insertion
405 of 2,3-DHB in the structure of the MQC membrane, indicating a structural difference
406 between the membranes before and after the insertion of 2,3-DHB. DSC analysis verified
407 that in the MQC and MDHB membranes the structure of the collagen triple helix was
408 preserved without deformation, corroborating with the FTIR results. The endothermic
409 peak of pure collagen, which occurs up to a temperature of 150 °C, was similar to that
410 found in the manufactured membranes [30,50].

411 **Fig. 3B** illustrates the X-ray diffraction of the membranes. In MQC, the two
412 largest peaks of chitosan diffraction in the microcrystalline state were found at 11.5° and
413 21.6° [22,51,52]. This last broad peak at 21.6° is also characteristic of collagen
414 maintaining the integrity of its triple helix, corroborating with observation with FTIR and
415 DSC [43,53,54]. In the MDHB membrane, the absence of a specific diffraction peak for
416 2,3-DHB confirms the uniform homogeneous dispersion of the substance in the polymeric
417 matrix corroborating again with the DSC results [55].

418 The porosity, swelling capacity, maximum stress at break, and thickness of the
419 MQC and MDHB membranes were also characterized (**Fig.4**).

420

421

422

423




Figure 4 - Porosity (A), swelling (B), maximum tensile strength (C), and membrane thickness (D) MQC and MDHB (* $p < 0.05$ and ** $p < 0.01$ using unpaired Student's t-test, $n = 5$).

424

425 The porosity percentage of the MQC membrane was 49.51%, while that of the
 426 MDHB membrane was 67.96%, as shown in **Fig.4A**. The addition of 2,3-DHB to the
 427 structure of the chitosan and collagen membrane not only increased its porosity by
 428 18.45%, but also fitted the MDHB membrane in the range of porosity considered ideal
 429 for a wound dressing, which is from 60 to 90% [33]. Porosity is an important factor, as it
 430 increases the surface area, promoting cell insertion and multiplication. In addition,
 431 porosity determines mechanical properties and water retention, so that it can readily
 432 absorb fluids present in a wound [37,40].

433 The increase in porosity of MDHB also increased the swelling capacity of this
 434 membrane (**Fig.4B**). The swelling properties of biomaterials is strongly dependent on the
 435 type and content of the polymers used. Biomaterials manufactured with collagen can have
 436 characteristics such as high porosity associated with high water absorption capacity

437 [56,57], making it a suitable material for use in the medical device industry. Chitosan is
438 also a biopolymer that has a high absorption capacity. Pallela, *et al.* [58] produced
439 biomaterials based on chitosan and chitosan/collagen with absorption capacity of 2400%
440 and 1000%, respectively. Xie *et al.* [59] produced wound dressing materials based on
441 chitosan/collagen with swelling capacity greater than 1000% both in saline solution and
442 in deionized water and PBS. The MDHB membrane showed a 661% increase in its
443 swelling capacity in comparison to MQC, probably due to other water-binding groups
444 after grafting the 2,3-DHB substance.

445 The maximum tensile strength measurements of the MQC and MDHB membranes
446 are found in the **Fig. 4C**. The results showed that the properties varied with the use of the
447 substance 2,3-DHB. The relatively high maximum burst stress exhibited by MDHB (0.07
448 Mpa) compared to MQC (0.05 Mpa) may be due to the increased number of ionic
449 interactions with the insertion of the 2,3-DHB structure in the membrane.

450 As previously reported by Susanto *et al.* [60], the membrane tensile strength of
451 less than 1.0 MPa is due to its constituent elements being purely natural materials, without
452 the use of additional crosslinking agents that could improve their mechanical properties.
453 The thickness of the membrane can also interfere with its mechanical property.
454 Valenzuela-Rojo *et al.* [37] produced membranes of chitosan and collagen by
455 lyophilization with a maximum stress of 0.21 MPa, which is greater than those found for
456 the membranes developed in the present study. However, the thickness of the membrane
457 tested by those researchers was 1.98 mm, while the thicknesses of the MQC and MDHB
458 membranes were 0.13 and 0.11 mm, respectively (**Fig.4D**). The smaller thickness of the
459 MDHB membrane in relation to the MQC, associated with the increase in the maximum
460 stress for the rupture of MDHB, evidences the influence of 2,3-DHB in improving the
461 mechanical property of the membrane.

462 The hydrophilicity of the MQC and MDHB membranes was determined by water
 463 contact angle measurements performed through the sessile drop method, during a time
 464 period between 0 to 60 seconds. **Fig. 5** demonstrates a marked decrease of the contact
 465 angle as a function of time.




Figure 5 - (A) Curves of the averages of contact angles with water as a function of time and (B) images of water droplets as a function of time in the MQC and MDHB membranes.

466

467 This analysis evidences that the incorporation of 2,3-DHB caused an increase of
 468 the hydrophilicity in the membrane, which is an interesting factor for materials that are
 469 intended to be used in the treatment of wounds, greatly affecting the interaction between
 470 the biomaterial and the tissue, favoring the adhesion of fibroblasts and endothelial cells
 471 during healing [15,61].

472

473 **3.2 Antioxidant activity**

474 The antioxidant property of the membranes was determined by the ABTS radical
 475 scavenging method. This method is widely used to assess the antioxidant capacity of


476 different compounds [62]. The antioxidant capacity is reflected in the ability of the sample
477 to decrease the color, reacting directly with the radical ABTS. The MQC membrane
478 showed $25.77 \pm 1.37\%$, while the MDHB membrane reduced $34.74 \pm 1.30\%$ in the ABTS
479 radicals. The presence of the 2,3-DHB substance provided an 8.97% increase in the
480 antioxidant capacity of the membrane.

481 The MQC membrane showed antioxidant activity due to chitosan. Pure chitosan
482 has previously reported antioxidant activity due to its amino and hydroxyl groups that
483 have the ability to reduce free radicals [63,64]. The MDHB membrane showed superior
484 antioxidant activity because 2,3-DHB is made up of a benzofuran ring structure. A series
485 of compounds based on benzofurans have antioxidant effects [65,66]. Furthermore, as
486 previously discussed, the inclusion of 2,3-DHB in the membrane promoted an increase in
487 available hydroxyl groups, which may also have contributed to the increase in antioxidant
488 activity. [67].

489

490 **3.3 Antileishmanial activity**

491 The inhibitory effect of MQC and MDHB membranes, the latter with
492 concentrations of 2,3-DHB ranging from 0.4 to $13 \mu\text{mol.L}^{-1}$, on the promastigote form of
493 *L. amazonensis* can be observed in **Fig.6**.



494

495

496 **Figure 6 - Effect of MQC and MDHB against the promastigote form of *Leishmania***
 497 ***amazonensis*.** The figure represents the mean of the percentage \pm standard error of the
 498 mean of the experiment carried out in duplicate. One-way ANOVA was performed to
 499 compare the groups with the control, with a significance level of *** $p < 0.001$.

500

501 All membranes inhibited the growth of the parasite; however, the MDHB
 502 membranes were better than the MQC membrane, exhibiting greater antileishmanial
 503 effect. In addition, the MDHB membranes had inhibitory effects superior to the positive
 504 control (Amphotericin B). **It was also observed that the inhibition of parasite growth was**
 505 **dependent on the concentration of 2,3-DHB in the membrane, exhibiting a dose-response**
 506 **effect in which the higher the concentration, the greater the inhibitory effect, reaching**
 507 **100% growth inhibition at the concentration of 13 $\mu\text{mol.L}^{-1}$.**

508 In the studies by Oliveira et al [9], 2,3-DHB alone at a concentration of 13 $\mu\text{mol.L}^{-1}$
 509 ¹ had an inhibited the growth of *L. amazonensis* by 86.76%, slightly lower than that of
 510 Amphotericin B (87.0%), but with the advantage of being more selective to the parasite.
 511 **In the present study,** the MDHB membrane presented an IC_{50} (0.081 $\mu\text{mol.L}^{-1}$) lower than

512 the IC₅₀ of 2,3-DHB (1.042 $\mu\text{mol.L}^{-1}$), being effective as a leishmanicide in all
513 concentrations studied.

514 The 2,3-DHB was effective in decreasing the number of amastigote forms of *L.*
515 *amazonensis* internalized by macrophages, in addition to decreasing the number of
516 amastigotes per infected macrophage [9]. The developed membranes may have these
517 characteristics also improved, which make them excellent candidates for advanced *in vivo*
518 studies.

519 The atomic force microscopy images prove the efficiency of the new membrane
520 manufactured on the parasite of *Leishmania amazonensis*. **Fig.7A** shows the typical
521 morphology of the *Leishmania* promastigote form, in the form of a spindle with an
522 anterior flagellum, similar to that already described by AFM and SEM [34].




Figure 7 - Atomic Force Microscopy (AFM) of *Leishmania amazonensis* promastigote cells. AFM amplitude images of untreated (control) cell (A), cells treated with 2,3-DHB at a concentration of 13 $\mu\text{mol.L}^{-1}$ (B), and with MDHB at a concentration of 13 $\mu\text{mol.L}^{-1}$ (C).

524 In the AFM images of the cells treated with 2,3-DHB and with MDHB,
525 considerable differences were found from the control. Disturbances occurred in cell body
526 membranes, with less elongated cells after treatment with 2,3-DHB (**Fig.7B**), proving that
527 the substance has an action on the microorganism. In the treatment with the MDHB
528 membrane, the cell body was not found, leaving only traces of the flagella (**Fig.7C**). This
529 result proves again the effectiveness of the new membrane developed here as a
530 leishmanicidal agent.

531 The decrease in cell length, leading to an ovoid and round shape has already been
532 described by Eaton *et al.* [34], when studying *Leishmania infantum* by AFM and SEM,
533 as being associated with the rupture of the membrane, indicating that 2,3-DHB acts
534 directly on the parasite's membrane, causing its death.

535

536 **3.4 Biocompatibility**

537 The cytotoxic effects of the MQC and MDHB membranes were investigated by
538 the MTT assay in fibroblasts - L929 and in keratinocytes - HaCaT (**Fig.8A-B**). These cell
539 lines were chosen because they represent cells present in the skin and participate in the
540 wound healing process [68,69]. In addition, SEM micrographs of fibroblasts treated with
541 the MDHB membrane (**Fig.8C**) were compared with the control (**Fig.8D**).




Figure 8 – Cell viability of fibroblasts - L929 (A) and keratinocytes – HaCaT (B) treated with MQC and MDHB by the MTT assay. Scanning electron microscopy (SEM) of fibroblasts - L929 not treated (C) and treated (D) with MDHB. In A and B, cell viability is represented by the mean \pm standard error of the experiment average performed in triplicate. One-way ANOVA was performed to compare groups with the control, with * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

542

543 In L929 (**Fig.8A**), cell viability was greater than 70%, for both MQC and MDHB,
544 for all concentrations tested, being higher than 80% for almost all concentrations, thus in
545 compliance with ISO 10993-5 [70]. These results are in agreement with other studies
546 carried out both *in vitro* and *in vivo*, which in addition to confirm the non-cytotoxicity of
547 chitosan/collagen membranes with fibroblasts, also evidence that biomaterials constituted
548 of these biopolymers stimulate its proliferation in wounds [15,60]. In addition, SEM
549 micrographs of fibroblasts treated with the MDHB membrane (**Fig.8D**) found no
550 morphological change in the cells when compared with the control (**Fig.8C**), as they

551 maintained their characteristic triangular shape, which reinforces the concept that
552 membranes are not cytotoxic.

553 The MQC and MDHB membranes also did not show cytotoxicity in human
554 keratinocytes (HaCaT). As it can be seen in **Fig.8B**, the membranes stimulated cell
555 proliferation in this lineage, obtaining a percentage of cell viability greater than 100% for
556 all concentrations tested. When comparing the cell viability of the keratinocytes treated
557 with the membranes, in all concentrations, the cell viability values of MDHB were higher
558 than those of MQC, indicating that the addition of 2,3-DHB to the membrane stimulated
559 cell proliferation in that lineage. As seen previously, the MDHB membranes maintained
560 the triple collagen helix and exhibited greater antioxidant activity than the MQC
561 membranes. This increase in antioxidant activity may have been responsible for the
562 increase in cell proliferation observed, since antioxidant substances may increase cell
563 proliferation in keratinocytes by providing a decrease in oxidative stress and or by
564 stimulating the intracellular activity of superoxide dismutase, a primary antioxidant
565 enzyme that catalyzes the dismutation reaction of the superoxide radical [71]. The
566 maintenance of the triple helix could be another factor responsible for the increase in cell
567 proliferation since all biological properties are dependent on its structure. The
568 proliferation of skin cells is important for the proper healing of wounds after injuries.
569 These results suggest, therefore, that the MDHB membrane, in addition to improving the
570 antileishmanial effect, can also increase the potential for skin tissue healing and
571 regeneration.

572

573 **3.4 Wound healing assay**

574 Wound healing is a complex process that involves the integrated response of
575 different cells and growth factors and results in the renewal of the structure and function

576 of the skin [72]. Chitosan and collagen are active materials for wound healing. Some
577 studies show that these materials accelerate healing, by stimulating cell proliferation, in
578 addition to preventing the development of infections [20,73,74]. In this work, after the
579 biocompatibility tests indicated their potential for wound healing and regeneration, the
580 cell migration capacity was tested in keratinocytes (HaCaT) treated with the formulated
581 membranes by performing an *in vitro* wound healing test (**Fig 9B**). The evolution of the
582 recovered wound area is illustrated in **Fig. 9A**.

583




Figure 9 - Representative micrographs of wounds on human keratinocytes (HaCaT) treated with MQC, MDHB, and control at different time intervals (A). Percentage of wound closure in the control cells, MQC and MDHB at different time intervals (B). The results are expressed as mean \pm standard error of three independent experiments performed in quadruplicate; * $p < 0.05$; ns indicates that there was no significant difference between treatments. The percentage of wound closure was calculated using the Image J software.

584

585 As shown in **Fig. 9A**, the tendency of the treated groups to close the wound was
586 assessed by the movement of the cells to fill the scratched area. In 24 h, the scratch of the
587 wounds treated with MQC, MDHB, and control exhibited a moderate degree of cell
588 migration resulting in partial wound closure, with no difference between materials. As
589 early as 48 h after the wound was made, HaCaT cells treated with the MDHB membrane
590 did not show significant differences in relation to the control, but exhibited a distinct

591 wound healing effect compared to cells treated with the MQC membrane, as they
592 migrated more quickly, with a migration rate about 19% higher, followed by complete
593 closure of the wound after evaluation in 72 h. Wound closure was complete for both
594 materials in 72 h along with the control. These results demonstrate that the MDHB
595 membrane creates an adequate environment for cell proliferation and growth.

596 Considering the healing capacity of human keratinocytes (HaCaT), as well as the
597 absence of cytotoxicity of the formulated membrane, the present work constitutes a
598 promising approach for the *in situ* treatment of cutaneous Leishmaniasis, which will be
599 validated with further investigation *in vivo*.

600

601 **4. CONCLUSION**

602 In the present work a new chitosan/collagen-based membrane incorporating 2,3-
603 DHB was successfully developed, maintaining the collagen integrity preserved without
604 deformation. The presence of the antileishmanial agent in the new membrane have
605 resulted in better mechanical properties and induced higher porosity, swelling capacity,
606 hydrophilicity and antioxidant activity. The antileishmanial activity tests against the
607 promastigote form of *Leishmania amazonensis* exhibited inhibitory effects superior to
608 those of Amphotericin B, which is used in the treatment of Leishmaniasis. It also
609 presented biocompatibility with L929 cells and stimulated the proliferation of HaCaT
610 cells. The healing tests demonstrated that the MDHB membrane has a suitable
611 environment for cell migration and growth. These results evidence that the formulated
612 membrane is a great candidate to be used in the treatment of cutaneous Leishmaniasis,
613 being indicated for advanced studies *in vivo*.

614

615

616 **ACKNOWLEDGMENTS**

617 The authors thank the Federal University of Piauí (UFPI) and the School of
618 Biotechnology of the Center for Biotechnology and Fine Chemistry (CBQF) of the
619 Catholic University of Porto for providing work research conditions (National Funds
620 from FCT - Fundação para a Ciência e a Tecnologia through project
621 UID/Multi/50016/2019). This study was financed in part by the Higher Education
622 Improvement Coordination - Brasil (Capes) - Finance Code 001, and the Brazilian
623 National Council for Scientific and Technological Development (306176/2019-0;
624 408635/2016-9 and 307460/2016-9).

625

626

627 **REFERENCES**

- 628 [1] Organização Pan-Americana da Saúde, Leishmanioses: Informe
629 Epidemiológico das Américas, Informe de Leishmanioses N° 7 1 (2019) 1–27.
- 630 [2] C.N. Dias, T.A.L. Nunes, J.M.S. Sousa, L.H. Costa, R.R.L. Rodrigues, A.J.
631 Araújo, J.D.B. Marinho Filho, M.V. Silva, M.R. Oliveira, F.A.A. Carvalho,
632 K.A.F. Rodrigues, 2020. Methyl gallate: Selective antileishmanial activity
633 correlates with host-cell directed effects. *Chem. Biol. Interact.* 320, 109026.
634 <https://doi.org/10.1016/j.cbi.2020.109026>.
- 635 [3] A.L.S. Santos, F.P. Matteoli, D.S. Gonçalves, S.H. Seabra, M.T. V. Romanos,
636 M.H. Branquinha, G.O. Resende, B.A. Cotrim, L.C.S. Aguiar, L.S. Sangenito,
637 2019. In vitro effects of the asymmetric peptidomimetic 157, containing L-
638 tartaric acid core and valine/leucine substituents, on *Leishmania amazonensis*
639 promastigotes and amastigotes. *Parasitol. Int.* 73, 101968.
640 <https://doi.org/10.1016/j.parint.2019.101968>.
- 641 [4] J.P.B. Menezes, C.E.S. Guedes, A.L.O.A. Petersen, D.B.M. Fraga, P.S.T.
642 Veras, 2015. Advances in development of new treatment for leishmaniasis,
643 *Biomed. Res. Int.* 2015, 815023. <https://doi.org/10.1155/2015/815023>.
- 644 [5] A.A.L. Sepúlveda, A.M.A. Velásquez, I.A.P. Linares, L. Almeida, C.R.
645 Fontana, C. Garcia, M.A.S. Graminha, 2020. Efficacy of photodynamic therapy
646 using TiO₂ nanoparticles doped with Zn and hypericin in the treatment of
647 cutaneous Leishmaniasis caused by *Leishmania amazonensis*. *Photodiagnosis*
648 *Photodyn. Ther.* 30, 101676. <https://doi.org/10.1016/j.pdpdt.2020.101676>.
- 649 [6] L.A. Carneiro, T.V. Santos, L.V. do R. Lima, P.K.S. Ramos, M.B. Campos,
650 F.T. Silveira, 2020. First report on feline leishmaniasis caused by *Leishmania*
651 (*Leishmania*) *amazonensis* in Amazonian Brazil. *Vet. Parasitol. Reg. Stud.*
652 *Reports.* 19, 100360. <https://doi.org/10.1016/j.vprsr.2019.100360>.
- 653 [7] L. Firmino-Cruz, T.D. Ramos, A.M. Fonseca-Martins, D. Oliveira-Maciel, G.
654 Oliveira-Silva, J.S. Santos, C. Cavazzoni, A. Morrot, D.C.O. Gomes, A.M. Vale,
655 D. Decoté-Ricardo, C.G. Freire-de-Lima, H.L. de M. Guedes, 2020. B-1
656 lymphocytes are able to produce IL-10, but is not pathogenic during *Leishmania*
657 (*Leishmania*) *amazonensis* infection. *Immunobiology.* 225, 151857.
658 <https://doi.org/10.1016/j.imbio.2019.10.006>.
- 659 [8] P. Scott, F.O. Novais, Cutaneous leishmaniasis: Immune responses in
660 protection and pathogenesis, *Nat. Rev. Immunol.* 16 (2016) 581–592.
661 <https://doi.org/10.1038/nri.2016.72>.
- 662 [9] L.G. de C. Oliveira, L.M. Brito, M.M. de M. Alves, L.V. Amorim, E.P.C.
663 Sobrinho-Júnior, C.E.S. Carvalho, K.A. da F. Rodrigues, D.D.R. Arcanjo, A.M.
664 das G.L. Citó, F.A. de A. Carvalho, In Vitro Effects of the Neolignan 2,3-
665 Dihydrobenzofuran Against *Leishmania Amazonensis*, *Basic. Clin. Pharmacol.*
666 *Toxicol.* 120 (2017) 52–58. <https://doi.org/10.1111/bcpt.12639>.

- 667 [10] A. Veeruraj, M. Arumugam, T. Ajithkumar, T. Balasubramanian, Isolation
668 and characterization of collagen from the outer skin of squid (*Doryteuthis*
669 *singhalensis*), *Food Hydrocoll.* 43 (2015) 708–716.
670 <https://doi.org/10.1016/j.foodhyd.2014.07.025>.
- 671 [11] L. Fan, J. Yi, J. Tong, X. Zhou, H. Ge, S. Zou, H. Wen, M. Nie, Preparation
672 and characterization of oxidized konjac glucomannan/carboxymethyl
673 chitosan/graphene oxide hydrogel, *Int. J. Biol. Macromol.* 91 (2016) 358–367.
674 <https://doi.org/10.1016/j.ijbiomac.2016.05.042>.
- 675 [12] O. Akturk, A. Tezcaner, H. Bilgili, M.S. Deveci, M.R. Gecit, D. Keskin,
676 Evaluation of sericin/collagen membranes as prospective wound dressing
677 biomaterial, *J. Biosci. Bioeng.* 112 (2011) 279–288.
678 <https://doi.org/10.1016/j.jbiosc.2011.05.014>.
- 679 [13] M. Li, M. Han, Y. Sun, Y. Hua, G. Chen, L. Zhang, Oligoarginine mediated
680 collagen/chitosan gel composite for cutaneous wound healing, *Int. J. Biol.*
681 *Macromol.* 122 (2019) 1120–1127.
682 <https://doi.org/10.1016/j.ijbiomac.2018.09.061>.
- 683 [14] A.E. Sorkio, E.P. Vuorimaa-Laukkanen, H.M. Hakola, H. Liang, T.A. Ujula,
684 J.J. Valle-Delgado, M. Österberg, M.L. Yliperttula, H. Skottman, Biomimetic
685 collagen I and IV double layer Langmuir-Schaefer films as microenvironment for
686 human pluripotent stem cell derived retinal pigment epithelial cells, *Biomaterials.*
687 51 (2015) 257–269. <https://doi.org/10.1016/j.biomaterials.2015.02.005>.
- 688 [15] M. Andonegi, K. Las Heras, E. Santos-Vizcaíno, M. Igartua, R.M.
689 Hernandez, K. de la Caba, P. Guerrero, 2020. Structure-properties relationship of
690 chitosan/collagen films with potential for biomedical applications. *Carbohydr.*
691 *Polym.* 237, 116159. <https://doi.org/10.1016/j.carbpol.2020.116159>.
- 692 [16] Z. Ruzczak, Effect of collagen matrices on dermal wound healing, *Adv.*
693 *Drug Deliv. Rev.* 55 (2003) 1595–1611.
694 <https://doi.org/10.1016/j.addr.2003.08.003>.
- 695 [17] K.M. Pawelec, S.M. Best, R.E. Cameron, Collagen: A network for
696 regenerative medicine, *J. Mater. Chem. B.* 4 (2016) 6484–6496.
697 <https://doi.org/10.1039/c6tb00807k>.
- 698 [18] E.M.A. Braz, S.C.C.C. Silva, D.A. Silva, F.A.A. Carvalho, H.M. Barreto,
699 L.S. Santos Júnior, E.C. Silva-Filho, Modified chitosan-based bioactive material
700 for antimicrobial application: Synthesis and characterization, *Int. J. Biol.*
701 *Macromol.* 117 (2018) 640–647. <https://doi.org/10.1016/j.ijbiomac.2018.05.205>.
- 702 [19] E.M.A. Braz, S.C.C.C. Silva, C.A.R.S. Brito, L.M. Brito, H.M. Barreto,
703 F.A.A. Carvalho, L.S. Santos Jr, A.O. Lobo, J.A. Osajima, K.S. Sousa, E.C.
704 Silva-Filho, 2020. Spectroscopic, thermal characterizations and bacteria
705 inhibition of chemically modified chitosan with phthalic anhydride. *Mater.*
706 *Chem. Phys.* 240, 122053. <https://doi.org/10.1016/j.matchemphys.2019.122053>.

- 707 [20] M.O.G. Ferreira, L.L.R. Leite, I.S. Lima, H.M. Barreto, L.C.C. Nunes, A.B.
708 Ribeiro, J.A. Osajima, E.C. Silva Filho, Chitosan Hydrogel in combination with
709 Nerolidol for healing wounds, *Carbohydr. Polym.* 152 (2016) 409–418.
710 <https://doi.org/10.1016/j.carbpol.2016.07.037>.
- 711 [21] M.O.G. Ferreira, I.S. de Lima, A.Í.S. Morais, S.O. Silva, R.B.F. de
712 Carvalho, A.B. Ribeiro, J.A. Osajima, E.C. Silva Filho, Chitosan associated with
713 chlorhexidine in gel form: Synthesis, characterization and healing wounds
714 applications, *J. Drug Deliv. Sci. Technol.* 49 (2019) 375–382.
715 <https://doi.org/10.1016/j.jddst.2018.12.003>.
- 716 [22] L.A. Pereira, L. da Silva Reis, F.A. Batista, A.N. Mendes, J.A. Osajima,
717 E.C. Silva-Filho, 2019. Biological properties of chitosan derivatives associated
718 with the ceftazidime drug. *Carbohydr. Polym.* 222, 115002.
719 <https://doi.org/10.1016/j.carbpol.2019.115002>.
- 720 [23] L.C.B. Lima, C.C. Coelho, F.C. Silva, A.B. Meneguim, H.S. Barud, R.D.S.
721 Bezerra, C. Viseras, J.A. Osajima, E.C. Silva Filho, 2019. Hybrid Systems Based
722 on Talc and Chitosan for Controlled Drug Release. *Materials.* 12, 3634.
723 <https://doi.org/10.1137/S0036139995293269>.
- 724 [24] M. Rezaii, S. Oryan, A. Javeri, Curcumin nanoparticles incorporated
725 collagen-chitosan scaffold promotes cutaneous wound healing through regulation
726 of TGF- β 1/Smad7 gene expression, *Materials Science and Engineering C.* 98
727 (2019) 347–357. <https://doi.org/10.1016/j.msec.2018.12.143>.
- 728 [25] D. Archana, B.K. Singh, J. Dutta, P.K. Dutta, Chitosan-PVP-nano silver
729 oxide wound dressing: In vitro and in vivo evaluation, *Int. J. Biol. Macromol.* 73
730 (2015) 49–57. <https://doi.org/10.1016/j.ijbiomac.2014.10.055>.
- 731 [26] S.S. Behera, U. Das, A. Kumar, A. Bissoyi, A.K. Singh, Chitosan/TiO₂
732 composite membrane improves proliferation and survival of L929 fibroblast
733 cells: Application in wound dressing and skin regeneration, *Int. J. Biol.*
734 *Macromol.* 98 (2017) 329–340. <https://doi.org/10.1016/j.ijbiomac.2017.02.017>.
- 735 [27] S. Kumar, J. Dutta, P.K. Dutta, Preparation and characterization of N-
736 heterocyclic chitosan derivative based gels for biomedical applications, *Int. J.*
737 *Biol. Macromol.* 45 (2009) 330–337.
738 <https://doi.org/10.1016/j.ijbiomac.2009.08.002>.
- 739 [28] M. Li, M. Han, Y. Sun, Y. Hua, G. Chen, L. Zhang, Oligoarginine mediated
740 collagen/chitosan gel composite for cutaneous wound healing, *Int. J. Biol.*
741 *Macromol.* 122 (2019) 1120–1127.
742 <https://doi.org/10.1016/j.ijbiomac.2018.09.061>.
- 743 [29] J. Si, Y. Yang, X. Xing, F. Yang, P. Shan, Controlled degradable chitosan /
744 collagen composite scaffolds for application in nerve tissue regeneration, *Polym.*
745 *Degrad. Stab.* 166 (2019) 73–85.
746 <https://doi.org/10.1016/j.polymdegradstab.2019.05.023>.

- 747 [30] A. Alagha, A. Nourallah, S. Hariri, 2020. Characterization of
748 dexamethasone loaded collagen-chitosan sponge and in vitro release study. *J.*
749 *Drug. Deliv. Sci. Technol.* 55, 101449.
750 <https://doi.org/10.1016/j.jddst.2019.101449>.
- 751 [31] A. Sionkowska, B. Kaczmarek, R. Gadzala-Kopciuch, Gentamicin release
752 from chitosan and collagen composites, *J. Drug Deliv. Sci. Technol.* 35 (2016)
753 353–359. <https://doi.org/10.1016/j.jddst.2016.09.001>.
- 754 [32] B.P. Antunes, A.F. Moreira, V.M. Gaspar, I.J. Correia, Chitosan/arginine-
755 chitosan polymer blends for assembly of nanofibrous membranes for wound
756 regeneration, *Carbohydr. Polym.* 130 (2015) 104–112.
757 <https://doi.org/10.1016/j.carbpol.2015.04.072>.
- 758 [33] M. Yin, Y. Wang, Y. Zhang, X. Ren, Y. Qiu, T.-S. Huang, 2020. Novel
759 quaternarized N-halamine chitosan and polyvinyl alcohol nanofibrous
760 membranes as hemostatic materials with excellent antibacterial properties.
761 *Carbohydr. Polym.* 232, 115823. <https://doi.org/10.1016/j.carbpol.2019.115823>.
- 762 [34] P. Eaton, C.R. Bittencourt, V.C. Silva, L.M.C. Vêras, C.H.N. Costa, M.J.
763 Feio, J.R.S.A. Leite, Anti-leishmanial activity of the antimicrobial peptide DRS
764 01 observed in *Leishmania infantum* (syn. *Leishmania chagasi*) cells,
765 *Nanomedicine.* 10 (2014) 483–490. <https://doi.org/10.1016/j.nano.2013.09.003>.
- 766 [35] P. de B. Policarpi, L. Turcatto, F. Demoliner, R.A. Ferrari, V.L.A.F.
767 Bascuñan, J.C. Ramos, I. Jachmanián, L. Vitali, G.A. Micke, J.M. Block,
768 Nutritional potential, chemical profile and antioxidant activity of Chichá
769 (*Sterculia striata*) nuts and its by-products, *Food Research International.* 106
770 (2018) 736–744. <https://doi.org/10.1016/j.foodres.2017.12.069>.
- 771 [36] B.I. Pinto, N.D. Cruz, O.R. Lujan, C.R. Propper, R.S. Kellar, 2019. In Vitro
772 Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration. *J. Vis.*
773 *Exp.* 144, e58838. <https://doi.org/10.3791/58838>.
- 774 [37] R.D. Valenzuela-Rojo, J. López-Cervantes, D.I. Sánchez-Machado, A.A.
775 Escárcega-Galaz, M. del R. Martínez-Macias, 2020. Antibacterial, mechanical
776 and physical properties of collagen - chitosan sponges from aquatic source.
777 *Sustain. Chem. Pharm.* 15, 100218. <https://doi.org/10.1016/j.scp.2020.100218>.
- 778 [38] X. Yu, L. Guo, M. Liu, X. Cao, S. Shang, Z. Liu, D. Huang, Y. Cao, F. Cui,
779 L. Tian, *Callicarpa nudiflora* loaded on chitosan-collagen/organomontmorillonite
780 composite membrane for antibacterial activity of wound dressing, *Int. J. Biol.*
781 *Macromol.* 120 (2018) 2279–2284.
782 <https://doi.org/10.1016/j.ijbiomac.2018.08.113>.
- 783 [39] A.L. Skwarczynska, D. Binias, W. Maniukiewicz, Z. Modrzejewska, T.E.L.
784 Douglas, The mineralization effect on chitosan hydrogel structure containing
785 collagen and alkaline phosphatase, *J. Mol. Struct.* 1187 (2019) 86–97.
786 <https://doi.org/10.1016/j.molstruc.2019.03.034>.

- 787 [40] P. Jithendra, A.M. Rajam, T. Kalaivani, A.B. Mandal, C. Rose, Preparation
788 and characterization of aloe vera blended Collagen-Chitosan composite scaffold
789 for tissue engineering applications, *ACS Appl. Mater. Interfaces*. 5 (2013) 7291–
790 7298. <https://doi.org/10.1021/am401637c>.
- 791 [41] N. Benbettaieb, O. Chambin, A. Assifaoui, S. Al-Assaf, T. Karbowiak, F.
792 Debeaufort, Release of coumarin incorporated into chitosan-gelatin irradiated
793 films, *Food Hydrocoll.* 56 (2016) 266–276.
794 <https://doi.org/10.1016/j.foodhyd.2015.12.026>.
- 795 [42] Y. Rajashekar, H.V. Kumar, K. V. Ravindra, N. Bakthavatsalam, Isolation
796 and characterization of biofumigant from leaves of *Lantana camara* for control of
797 stored grain insect pests, *Ind. Crops Prod.* 51 (2013) 224–228.
798 <https://doi.org/10.1016/j.indcrop.2013.09.006>.
- 799 [43] H. Goodarzi, K. Jadidi, S. Pourmotabed, E. Sharifi, H. Aghamollaei,
800 Preparation and in vitro characterization of cross-linked collagen – gelatin
801 hydrogel using EDC/NHS for corneal tissue engineering applications, *Int. J. Biol.*
802 *Macromol.* 126 (2019) 620–632. <https://doi.org/10.1016/j.ijbiomac.2018.12.125>.
- 803 [44] A.M. Abdel-Mohsen, R.M. Abdel-Rahman, I. Kubena, L. Kobera, Z. Spatz,
804 M. Zboncak, R. Prikryl, J. Brus, J. Jancar, 2020. Chitosan-glucan complex
805 hollow fibers reinforced collagen wound dressing embedded with aloe vera. Part
806 I: Preparation and characterization. *Carbohydr. Polym.* 230, 115708.
807 <https://doi.org/10.1016/j.carbpol.2019.115708>.
- 808 [45] J.M. Pachence, Collagen-based devices for soft tissue repair, *J. Biomed.*
809 *Mater. Res.* 33 (1996) 35–40. [https://doi.org/10.1002/\(SICI\)1097-
810 4636\(199621\)33:1<35::AID-JBM6>3.0.CO;2-N](https://doi.org/10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N).
- 811 [46] M. Gierszewska, J. Ostrowska-Czubenko, Chitosan-based membranes with
812 different ionic crosslinking density for pharmaceutical and industrial
813 applications, *Carbohydr. Polym.* 153 (2016) 501–511.
814 <https://doi.org/10.1016/j.carbpol.2016.07.126>.
- 815 [47] M.J. Boggione, C.R.A. Mahl, M.M. Beppu, B. Farruggia, Synthesis and
816 characterization of chitosan membranes functionalized with amino acids and
817 copper for adsorption of endoglucanase, *Powder Technol.* 315 (2017) 250–257.
818 <https://doi.org/10.1016/j.powtec.2017.04.014>.
- 819 [48] N. Nematidil, M. Sadeghi, S. Nezami, H. Sadeghi, 2019. Synthesis and
820 characterization of Schiff-base based chitosan-g-glutaraldehyde/NaMMTNPs-
821 APTES for removal Pb²⁺ and Hg²⁺ ions. *Carbohydr. Polym.* 222, 114971.
822 <https://doi.org/10.1016/j.carbpol.2019.114971>.
- 823 [49] X. Huo, W. Li, Y. Wang, N. Han, J. Wang, N. Wang, X. Zhang, Chitosan
824 composite microencapsulated comb-like polymeric phase change material via
825 coacervation microencapsulation, *Carbohydr. Polym.* 200 (2018) 602–610.
826 <https://doi.org/10.1016/j.carbpol.2018.08.003>.

- 827 [50] A. George, A. Veis, FTIRS in H₂O Demonstrates That Collagen Monomers
828 Undergo a Conformational Transition Prior to Thermal Self-Assembly in Vitro,
829 *Biochemistry*. 30 (1991) 2372–2377. <https://doi.org/10.1021/bi00223a011>.
- 830 [51] R. Huang, W. Li, X. Lv, Z. Lei, Y. Bian, H. Deng, H. Wang, J. Li, X. Li,
831 Biomimetic LBL structured nano fibrous matrices assembled by
832 chitosan/collagen for promoting wound healing, *Biomaterials*. 53 (2015) 58–75.
833 <https://doi.org/10.1016/j.biomaterials.2015.02.076>.
- 834 [52] L. Sun, J. Han, Z. Liu, S. Wei, X. Su, G. Zhang, The facile fabrication of
835 wound compatible anti-microbial nanoparticles encapsulated Collagenous
836 Chitosan matrices for effective inhibition of poly- microbial infections and
837 wound repairing in burn injury care : Exhaustive in vivo evaluations, *J.*
838 *Photochem. Photobiol. B*. 197 (2019) 111539.
839 <https://doi.org/10.1016/j.jphotobiol.2019.111539>.
- 840 [53] G.C. Jayakumar, N. Usharani, K. Kawakami, J.R. Rao, B.U. Nair,
841 Preparation of antibacterial collagen – pectin particles for biotherapeutics, *RSC*
842 *Adv.* 4 (2014) 42846–42854. <https://doi.org/10.1039/C4RA07683D>.
- 843 [54] A. Maged, A.A. Abdelkhalek, A.A. Mahmoud, S. Salah, M.M. Ammar,
844 M.M. Ghorab, Mesenchymal stem cells associated with chitosan scaffolds loaded
845 with rosuvastatin to improve wound healing, *European Journal of Pharmaceutical*
846 *Sciences*. 127 (2019) 185–198. <https://doi.org/10.1016/j.ejps.2018.11.002>.
- 847 [55] P.R. Sivashankari, M. Prabakaran, Three-dimensional porous scaffolds
848 based on agarose / chitosan / graphene oxide composite for tissue engineering,
849 *Int. J. Biol. Macromol.* 146 (2020) 222–231.
850 <https://doi.org/10.1016/j.ijbiomac.2019.12.219>.
- 851 [56] H.J. Lee, S.H. Ahn, G.H. Kim, Three-dimensional collagen/alginate hybrid
852 scaffolds functionalized with a drug delivery system (DDS) for bone tissue
853 regeneration, *Chemistry of Materials*. 24 (2012) 881–891.
854 <https://doi.org/10.1021/cm200733s>.
- 855 [57] J. Elango, J. Zhang, B. Bao, K. Palaniyandi, S. Wang, W. Wu, J.S.
856 Robinson, Rheological, biocompatibility and osteogenesis assessment of fish
857 collagen scaffold for bone tissue engineering, *Int. J. Biol. Macromol.* 91 (2016)
858 51–59. <https://doi.org/10.1016/j.ijbiomac.2016.05.067>.
- 859 [58] R. Pallela, J. Venkatesan, V.R. Janapala, S.K. Kim, Biophysicochemical
860 evaluation of chitosan-hydroxyapatite-marine sponge collagen composite for
861 bone tissue engineering, *Journal of Biomedical Materials Research A*. 100A
862 (2012) 486–495. <https://doi.org/10.1002/jbm.a.33292>.
- 863 [59] H. Xie, X. Chen, X. Shen, Y. He, W. Chen, Q. Luo, W. Ge, W. Yuan, X.
864 Tang, D. Hou, D. Jiang, Q. Wang, Y. Liu, Q. Liu, K. Li, Preparation of chitosan-
865 collagen-alginate composite dressing and its promoting effects on wound healing,
866 *Int. J. Biol. Macromol.* 107 (2018) 93–104.
867 <https://doi.org/10.1016/j.ijbiomac.2017.08.142>.

- 868 [60] A. Susanto, S. Susanah, B.P. Priosoeryanto, M.H. Satari, I. Komara, The
869 effect of the chitosan-collagen membrane on wound healing process in rat
870 mandibular defect, *J. Indian. Soc. Periodontol.* 23 (2019) 113–118.
871 https://doi.org/10.4103/jisp.jisp_232_18.
- 872 [61] A.T. Shah, S. Zahid, F. Ikram, M. Maqbool, A.A. Chaudhry, M.I. Rahim, F.
873 Schmidt, O. Goerke, A.S. Khan, I. ur Rehman, 2019. Tri-layered functionally
874 graded membrane for potential application in periodontal regeneration. *Materials*
875 *Science and Engineering C.* 103, 109812.
876 <https://doi.org/10.1016/j.msec.2019.109812>.
- 877 [62] A. Mocan, A. Diuzheva, S. Bădărău, C. Moldovan, V. Andruch, S.
878 Carradori, C. Campestre, A. Tartaglia, M. Simone, D. Vodnar, M. Tiecco, R.
879 Germani, G. Crișan, M. Locatelli, 2019. Liquid phase and microwave-assisted
880 extractions for multicomponent phenolic pattern determination of five Romanian
881 Galium species coupled with bioassays. *Molecules.* 24, 1226.
882 <https://doi.org/10.3390/molecules24071226>.
- 883 [63] X. Han, Y. Mi, Y. Ji, M. Sun, H. Tang, F. Dong, Z. Guo, 2024. A novel
884 chitosan antioxidant bearing sulfhydryl group: Synthesis, characterization and
885 activity assessment. *Int. J. Biol. Macromol.* 261, 129816.
886 <https://doi.org/10.1016/j.ijbiomac.2024.129816>.
- 887 [64] W. Tan, J. Zhang, X. Zhao, F. Dong, Q. Li, Z. Guo, Synthesis and
888 antioxidant action of chitosan derivatives with amino-containing groups via
889 azide-alkyne click reaction and N-methylation, *Carbohydr. Polym.* 199 (2018)
890 583–592. <https://doi.org/10.1016/j.carbpol.2018.07.056>.
- 891 [65] S. Rindhe, M. Rode, B. Karale, 2010. New benzofuran derivatives as an
892 antioxidant agent, *Indian J. Pharm. Sci.* 72, 231. [https://doi.org/10.4103/0250-](https://doi.org/10.4103/0250-474X.65022)
893 [474X.65022](https://doi.org/10.4103/0250-474X.65022).
- 894 [66] J. Cho, C. Park, Y. Lee, S. Kim, S. Bose, M. Choi, A.S. Kumar, J.-K. Jung,
895 H. Lee, Neuroprotective and Antioxidant Effects of Novel Benzofuran-2-
896 Carboxamide Derivatives, *Biomol. Ther. (Seoul).* 23 (2015) 275–282.
897 <https://doi.org/10.4062/biomolther.2015.030>.
- 898 [67] T. Zheng, P. Tang, G. Li, 2023. Development of composite film based on
899 collagen and phenolic acid-grafted chitosan for food packaging. *Int. J. Biol.*
900 *Macromol.* 241, 124494. <https://doi.org/10.1016/j.ijbiomac.2023.124494>.
- 901 [68] A.C.L. Campos, A. Borges-Branco, A.K. Groth, Wound healing, ABCD.
902 *Arquivos Brasileiros de Cirurgia Digestiva.* 20 (2007) 51–58.
903 <https://doi.org/10.1590/S0102-67202007000100010>.
- 904 [69] C.A. Balbino, L.M. Pereira, R. Curi, Mechanisms involved in wound
905 healing: a revision, *Brazilian Journal of Pharmaceutical Sciences.* 41 (2005) 27–
906 51. <https://doi.org/10.1590/s1516-93322005000100004>.

- 907 [70] International Organization for Standardization, Biological evaluation of
908 medical devices. Part 5: tests for in vitro cytotoxicity, 3rd ed., ISO 10993-5
909 Switzerland, 2009.
- 910 [71] N. Thitilertdecha, P. Chaiwut, N. Saewan, 2020. In vitro antioxidant
911 potential of *Nephelium lappaceum* L. rind extracts and geraniin on human
912 epidermal keratinocytes. *Biocatal. Agric. Biotechnol.* 23, 101482.
913 <https://doi.org/10.1016/j.bcab.2019.101482>.
- 914 [72] F. Blažević, T. Milekić, M.D. Romić, M. Juretić, I. Pepić, J. Filipović-Grčić,
915 J. Lovrić, A. Hafner, Nanoparticle-mediated interplay of chitosan and melatonin
916 for improved wound epithelialisation, *Carbohydr. Polym.* 146 (2016) 445–454.
917 <https://doi.org/10.1016/j.carbpol.2016.03.074>.
- 918 [73] V. Patrulea, V. Ostafe, G. Borchard, O. Jordan, Chitosan as a starting
919 material for wound healing applications, *European Journal of Pharmaceutics and*
920 *Biopharmaceutics.* 97 (2015) 417–426.
921 <https://doi.org/10.1016/j.ejpb.2015.08.004>.
- 922 [74] R. Guo, S. Xu, L. Ma, A. Huang, C. Gao, The healing of full-thickness burns
923 treated by using plasmid DNA encoding VEGF-165 activated collagen-chitosan
924 dermal equivalents, *Biomaterials.* 32 (2011) 1019–1031.
925 <https://doi.org/10.1016/j.biomaterials.2010.08.087>.
- 926